ArticleVeterinary and animal science2025
A nuclear magnetic resonance spectroscopy metabolomic approach to renal dysfunction in canine leishmaniasis.
Article in Veterinary and animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NMR Metabolomics in Veterinary Medicine: From Biomarker Discovery to Clinical Implementation.Veterinary sciences · 2026Review
- Benchtop NMR in Biomedicine: An Updated Literature Overview.Metabolites · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a major complication and the leading cause of mortality in canine leishmaniasis (CanL). The kidneys are essential for numerous metabolic processes, and specific metabolites may serve as predictive biomarkers of kidney function. Nuclear Magnetic Resonance (NMR) spectroscopy is a prominent analytical tool in metabolomics, capable of identifying metabolites in urine. This study aim to identify distinct patterns in the NMR spectra of urine samples from dogs with CKD in CanL, reflecting the underlying metabolic profiles Fifty-five dogs were divided into three groups: 14 healthy control dogs (CG), 33 dogs with CKD secondary to leishmaniasis, and 8 dogs with CKD unrelated to leishmaniasis. CanL dogs were classified according to the International Renal Interest Society (IRIS) staging system: stage 1 (15 dogs), stage 2 (10 dogs), stage 3 (6 dogs), and stage 4 (2 dogs); and by LeishVet guidelines: stage I (5 dogs), stage II (4 dogs), stage III (14 dogs), and stage IV (10 dogs). Among dogs with CKD alone, one dog was in IRIS stage 1, two in stage 2, one in stage 3, and four in stage 4. Low-field proton nuclear magnetic resonance (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.